The global digital therapeutics market is growing as healthcare stakeholders invest in software-based therapeutic solutions to improve patient outcomes and reduce healthcare costs. The market was valued at USD 9.59 billion in 2024 and is projected to reach USD 82.07 billion by 2035, growing at a CAGR of 21.55%.

The Digital Therapeutics Market includes chronic disease management, mental health disorders, preventive care, general wellness applications, software, devices, platforms, patients, providers, payers, employers, diabetes, cardiology, neurology, oncology therapeutic areas.

Patients represent the largest end-user share at 52.4% due to app-store accessibility and self-pay options. Many commercially available applications, particularly for weight management, stress reduction, and sleep improvement, operate outside traditional prescription frameworks, driving direct-to-consumer adoption.

Payers and insurers are emerging as the fastest-growing end-user segment at 23.8% CAGR as Medicare, Medicaid, and commercial plans expand formulary coverage for FDA-cleared products. This segment benefits from reimbursement code expansion and cost-containment objectives.

Providers and hospitals also contribute substantially to the market, though they occupy smaller portions of the overall landscape. Growth trends indicate a robust demand for digital therapeutic solutions supporting diverse scientific and clinical needs across various healthcare settings.

Akili Interactive continues expanding digital therapeutic capabilities and pediatric ADHD gaming therapeutic development. The company's FDA-cleared prescription video game is strengthening its position in the digital therapeutics market.

Better Therapeutics continues advancing cardiometabolic disease and type 2 diabetes digital therapeutic solutions. The company's FDA-cleared CBT-based liver and cardio modules are supporting increasing clinical demand for effective disease management solutions.

The future market will depend on regulatory harmonization, AI-driven personalization, rising chronic-disease prevalence, payer reimbursement expansion, pharma-DTx co-development partnerships, and mobile-infrastructure maturity in emerging markets.

FAQs

Q1. Why do patients dominate the digital therapeutics market end-user segment?
Patients dominate due to app-store accessibility, self-pay options, and direct-to-consumer availability of digital therapeutic applications.

Q2. What is driving the growth of payers and insurers?
Medicare, Medicaid, and commercial plan expansion of formulary coverage for FDA-cleared products is driving payer and insurer adoption.

Tags: digital therapeutics market, patients, payers, insurers, end users